|
C15ORF40 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.52389997579661E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.21349999124976E-09 |
| Normal-vs-Stage2 |
1.444300E-02 |
| Normal-vs-Stage3 |
3.67860000016762E-07 |
| Normal-vs-Stage4 |
3.13930004214313E-09 |
| Stage1-vs-Stage2 |
1.189040E-01 |
| Stage1-vs-Stage3 |
9.829200E-01 |
| Stage1-vs-Stage4 |
3.865800E-02 |
| Stage2-vs-Stage3 |
1.178040E-01 |
| Stage2-vs-Stage4 |
7.002300E-03 |
| Stage3-vs-Stage4 |
6.405700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.72909958257628E-10 |
| Normal-vs-AfricanAmerican |
3.223500E-03 |
| Normal-vs-Asian |
3.297600E-02 |
| Caucasian-vs-AfricanAmerican |
2.372400E-01 |
| Caucasian-vs-Asian |
3.924100E-03 |
| AfricanAmerican-vs-Asian |
4.069800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.81359996307162E-09 |
| Normal-vs-Female |
6.61619999897667E-08 |
| Male-vs-Female |
2.009600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.73849967544504E-10 |
| Normal-vs-Age(41-60Yrs) |
4.31300000000023E-05 |
| Normal-vs-Age(61-80Yrs) |
6.73000000173118E-08 |
| Normal-vs-Age(81-100Yrs) |
9.958000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.446000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.164800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.336400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.281150E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.799200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.495400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.914600E-01 |
| Classical-VS-Follicular |
1.544280E-02 |
| Classical-VS-Other |
3.178000E-01 |
| Classical-VS-Normal |
6.55789977876964E-10 |
| Tall-VS-Follicular |
5.048100E-02 |
| Tall-VS-Other |
2.418600E-01 |
| Tall-VS-Normal |
3.09649999996608E-06 |
| Follicular-VS-Other |
9.496400E-01 |
| Follicular-VS-Normal |
2.461400E-03 |
| Other-VS-Normal |
1.391970E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.81239E-05 |
| Normal-vs-N1 |
1.90170001967971E-09 |
| N0-vs-N1 |
8.876700E-03 |
|
|
